XTRA:PA8

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide.


Snowflake Analysis

High growth potential with excellent balance sheet.

Share Price & News

How has Paion's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PA8's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

16.1%

PA8

-1.5%

DE Biotechs

6.8%

DE Market


1 Year Return

18.8%

PA8

10.4%

DE Biotechs

5.6%

DE Market

Return vs Industry: PA8 exceeded the German Biotechs industry which returned 10.3% over the past year.

Return vs Market: PA8 exceeded the German Market which returned 4.4% over the past year.


Shareholder returns

PA8IndustryMarket
7 Day16.1%-1.5%6.8%
30 Day37.5%8.1%14.0%
90 Day25.9%10.2%7.5%
1 Year18.8%18.8%10.8%10.4%7.4%5.6%
3 Year-7.5%-7.5%13.9%12.4%0.3%-7.3%
5 Year5.1%4.2%19.5%17.4%12.4%-2.0%

Price Volatility Vs. Market

How volatile is Paion's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Paion undervalued compared to its fair value and its price relative to the market?

11.04x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PA8's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PA8's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PA8 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PA8 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PA8's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PA8 is overvalued based on its PB Ratio (11x) compared to the DE Biotechs industry average (4.8x).


Next Steps

Future Growth

How is Paion forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

102.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PA8 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: PA8 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PA8's is expected to become profitable in the next 3 years.

Revenue vs Market: PA8's revenue (47.8% per year) is forecast to grow faster than the German market (5.7% per year).

High Growth Revenue: PA8's revenue (47.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PA8's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Paion performed over the past 5 years?

26.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PA8 is currently unprofitable.

Growing Profit Margin: PA8 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PA8 is unprofitable, but has reduced losses over the past 5 years at a rate of 26.6% per year.

Accelerating Growth: Unable to compare PA8's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PA8 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).


Return on Equity

High ROE: PA8 has a negative Return on Equity (-37.24%), as it is currently unprofitable.


Next Steps

Financial Health

How is Paion's financial position?


Financial Position Analysis

Short Term Liabilities: PA8's short term assets (€22.6M) exceed its short term liabilities (€10.2M).

Long Term Liabilities: PA8's short term assets (€22.6M) exceed its long term liabilities (€25.6K).


Debt to Equity History and Analysis

Debt Level: PA8 is debt free.

Reducing Debt: PA8 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PA8 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PA8 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Paion's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PA8's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PA8's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PA8's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PA8's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PA8's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Jim Phillips (57yo)

0.67

Tenure

€619,949

Compensation

Dr. James Neil Phillips, also known as Jim, MB, ChB, M.D., MBA, serves as Chairman of Management Board and Chief Executive Officer of Paion AG since October 16, 2019. Dr. Phillips serves as the Chief Execu ...


CEO Compensation Analysis

Compensation vs Market: Jim's total compensation ($USD702.25K) is about average for companies of similar size in the German market ($USD697.68K).

Compensation vs Earnings: Insufficient data to compare Jim's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
James Phillips
CEO & Chairman of Management Board0.67yr€619.95kno data
Abdelghani Omari
CFO & Member of Management Board5.75yrs€285.13kno data
Jürgen Beck
Chief Development Officer & Member of Management Board2.5yrs€285.13k0.015% 25.3k
Ralf Penner
Vice President of Investor Relations & Public Relationsno datano datano data

2.5yrs

Average Tenure

Experienced Management: PA8's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jörg Spiekerkötter
Chairman of Supervisory Board10.08yrs€50.00kno data
Karen Louise Dorrepaal
Independent Vice Chairman of Supervisory Boardno data€37.50kno data
Hans Tanner
Member of Supervisory Board3yrs€25.00kno data
Markus Dieken
Member of Supervisory Board1.08yrs€14.17kno data
Irina Antonijevic
Independent Member of Supervisory Board3yrs€25.00kno data

3.0yrs

Average Tenure

59.5yo

Average Age

Experienced Board: PA8's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.6%.


Top Shareholders

Company Information

Paion AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Paion AG
  • Ticker: PA8
  • Exchange: XTRA
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €165.700m
  • Shares outstanding: 65.49m
  • Website: https://www.paion.com

Number of Employees


Location

  • Paion AG
  • Martinstrasse 10-12
  • Aachen
  • North Rhine-Westphalia
  • 52062
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PA8DB (Deutsche Boerse AG)YesBearer SharesDEEURFeb 2005
PAIO.FOTCPK (Pink Sheets LLC)YesBearer SharesUSUSDFeb 2005
PA8XTRA (XETRA Trading Platform)YesBearer SharesDEEURFeb 2005
0NF3LSE (London Stock Exchange)YesBearer SharesGBEURFeb 2005
PA8DBATS-CHIXE (BATS 'Chi-X Europe')YesBearer SharesGBEURFeb 2005
PA8ETLX (Eurotlx)YesBearer SharesITEURFeb 2005

Biography

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company’s lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 22:03
End of Day Share Price2020/06/05 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.